Enliven Therapeutics, Inc. (ELVN)

In the past six months, Enliven Therapeutics' stock price was $18.81 as of July 31, 2025, with a 52-week range of $13.30 to $30.03. In August 2025, the company reported positive data from the ENABLE Phase 1 trial of ELVN-001 and announced a public offering generating $230 million, extending its cash runway into the first half of 2029. As of June 30, 2025, the company had $490.5 million in cash, cash equivalents, and marketable securities. In September 2025, the stock closed at $20.01 on September 26 and $18.57 on September 25. On October 17, 2025, the stock closed at $21.39, with analysts giving it a "Strong Buy" rating and a $40.14 price target, indicating a potential upside of 94.76%.

The demand for Enliven Therapeutics' products is not subject to typical seasonal fluctuations. Demand for its products, once approved, would be driven by the prevalence of the specific cancer types they target and the efficacy and safety profile of the treatments, rather than seasonal patterns. The company's current focus is on clinical trials and development, not commercial sales, so demand seasonality for its services is not applicable in the traditional sense.

Enliven Therapeutics, Inc. (ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to improve oncology patient outcomes. The company aims to address unmet needs in cancer treatment through precision oncology, developing kinase inhibitors to enhance efficacy, combat resistance, address brain metastases, and improve safety and patient convenience. Its major product candidates include ELVN-001, a kinase inhibitor for CML in Phase 1 trials, and ELVN-002, a HER2 inhibitor in Phase 1 trials for NSCLC and other HER2-driven cancers.

Enliven Therapeutics is headquartered in Boulder, Colorado, United States. Its geographic footprint primarily revolves around its research and development activities and clinical trials, which are conducted across various sites.

Enliven Therapeutics' brand reputation has been positively influenced by its clinical progress and financial stability. Positive clinical data for ELVN-001 in CML and a strengthened balance sheet contribute to a favorable perception. No specific events negatively impacted the company's reputation in the past year.

The provided search results do not offer specific details on major institutional and individual owners of Enliven Therapeutics, Inc. (ELVN).